ArticleFrontiers in medicine2026
Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) and systemic lupus erythematosus (SLE) are distinct autoimmune entities that can present with overlapping clinical features of non-scarring alopecia. We report a case of a 35-year-old woman with a 9-month history of severe, progressive patchy alopecia that was refractory to baricitinib. Subsequent serological workup led to a diagnosis of SLE. The patient demonstrated significant clinical improvement following treatment with the selective Janus kinase (JAK) 1 inhibitor ivarmacitinib. Trichoscopy performed 8 months post-treatment revealed features supportive of both AA (exclamation mark hairs, black dots, broken hairs, yellow dots) and lupus-associated alopecia (follicular telangiectasia), suggesting coexisting AA and SLE. This case highlights the diagnostic challenge posed by overlapping hair loss disorders and provides preliminary evidence for the potential therapeutic utility of ivarmacitinib in this clinical context. Furthermore, we sought further evidence from the literature to support the use of JAK inhibitors in lupus-associated alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.